var title_f25_18_25888="Breast MRI of occult primary breast cancer";
var content_f25_18_25888=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F58055&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F58055&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Breast MRI of occult primary breast cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 261px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Breast MRI can be useful for identifying an occult primary breast cancer when a patient presents with an unknown primary cancer. This MRI depicts a patient who presented with an axillary lymph node metastasis with an unremarkable clinical breast examination and a negative mammogram. The MRI detected a 6 mm suspiciously enhancing irregular mass in the outer inferior right breast (arrow). Biopsy revealed an invasive lobular carcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_18_25888=[""].join("\n");
var outline_f25_18_25888=null;
var title_f25_18_25889="Cetylpyridinium and benzocaine: Drug information";
var content_f25_18_25889=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cetylpyridinium and benzocaine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F149099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cepacol&reg;;",
"     </li>",
"     <li>",
"      Kank-A&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F149104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Local Anesthetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F149100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antiseptic/anesthetic: Oral: Dissolve in mouth as needed for sore throat",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antiseptic/anesthetic (dental use): Oral: Dissolve in mouth as needed for pain",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F149101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F4423365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11217374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F149095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic relief of sore throat",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F149091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F149097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Merocaine (GB, IE);",
"     </li>",
"     <li>",
"      Prodol (ZA);",
"     </li>",
"     <li>",
"      Septolete (EE)",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8854 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-C070ECA3F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_18_25889=[""].join("\n");
var outline_f25_18_25889=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149099\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149104\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149100\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149101\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4423365\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11217374\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149095\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299008\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149091\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149097\">",
"      International Brand Names",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8854\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8854|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_18_25890="Anencephaly ultrasound";
var content_f25_18_25890=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 592px\">",
"   <div class=\"ttl\">",
"    Anencephaly at 32 postmenstrual weeks of gestation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 572px; height: 187px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A coronal view of the face. the eyes are prominent and above them no cranial vault or brain tissue is seen (A). A longitudinal view of the neck region and upper thoracic vertebrae showing the disrupted bony structures as well as some disorganized neutral tissue (B). In a transverse view the typical U-shaped vertebrae with tissue protruding is evident. This is consistent with an open upper spina bifida which is commonly seen with anencephaly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ana Monteagudo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_18_25890=[""].join("\n");
var outline_f25_18_25890=null;
var title_f25_18_25891="Potassium balance in acid-base disorders";
var content_f25_18_25891=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Potassium balance in acid-base disorders",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/18/25891/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/18/25891/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/18/25891/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/18/25891/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/18/25891/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/18/25891/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/18/25891/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are important interactions between potassium and acid-base balance that involve both transcellular cation exchanges and alterations in renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25891/abstract/1\">",
"     1",
"    </a>",
"    ]. These changes are most pronounced with metabolic acidosis but can also occur with metabolic alkalosis and, to a lesser degree, respiratory acid-base disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ACID-BASE DISORDERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Metabolic acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In metabolic acidosis, more than one-half of the excess hydrogen ions is buffered in the cells. In this setting, electroneutrality is maintained in part by the movement of intracellular potassium into the extracellular fluid (",
"    <a class=\"graphic graphic_figure graphicRef68866 \" href=\"UTD.htm?9/25/9628\">",
"     figure 1",
"    </a>",
"    ). Thus, metabolic acidosis results in a plasma potassium concentration that is elevated in relation to total body stores. The net effect in some cases is overt hyperkalemia; in other patients who are potassium depleted due to urinary or gastrointestinal losses, the plasma potassium concentration is normal or even reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25891/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. There is still a relative increase in the plasma potassium concentration, however, as evidenced by a further fall in the plasma potassium concentration if the acidemia is corrected.",
"   </p>",
"   <p>",
"    On average, the plasma potassium concentration will rise by 0.6",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    (range 0.2 to 1.7",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    for every 0.1 unit reduction in extracellular pH [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25891/abstract/4\">",
"     4",
"    </a>",
"    ]. The wide range, however, means that the degree to which the plasma potassium concentration will fall with treatment of the acidemia cannot be accurately predicted. Thus, careful monitoring is required.",
"   </p>",
"   <p>",
"    A fall in pH is much less likely to raise the plasma potassium concentration in patients with lactic acidosis or ketoacidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25891/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The hyperkalemia that is commonly seen in diabetic ketoacidosis, for example, is more closely related to the insulin deficiency and hyperosmolality than to the degree of acidemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=see_link\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Why this occurs is not well understood. Two factors that may contribute are the ability of the organic anion to accompany the hydrogen ion into the cell, perhaps as the lipid-soluble, intact acid [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25891/abstract/6\">",
"     6",
"    </a>",
"    ], and differential effects on insulin and glucagon secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25891/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Just as metabolic acidosis can cause hyperkalemia, a rise in the plasma potassium concentration can induce a mild metabolic acidosis. Two factors contribute to this phenomenon:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A transcellular exchange occurs as the entry of most of the excess potassium into the cells is balanced in part by intracellular hydrogen ions moving into the extracellular fluid [",
"      <a class=\"abstract\" href=\"UTD.htm?25/18/25891/abstract/9\">",
"       9",
"      </a>",
"      ]. The net effect is an extracellular acidosis and an intracellular alkalosis.",
"     </li>",
"     <li>",
"      The rise in cell pH within the renal tubular cells has an important effect on net acid excretion (primarily as ammonium). The kidney appropriately increases acid excretion after an acid load, an effect that is mediated in part by a fall in intracellular pH [",
"      <a class=\"abstract\" href=\"UTD.htm?25/18/25891/abstract/10\">",
"       10",
"      </a>",
"      ]. On the other hand, the intracellular alkalosis induced by hyperkalemia diminishes ammonium formation, thereby preventing excretion of the daily acid load. In patients with hypoaldosteronism, for example, the mild metabolic acidosis is primarily due to the associated hyperkalemia [",
"      <a class=\"abstract\" href=\"UTD.htm?25/18/25891/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10089?source=see_link\">",
"       \"Chapter 11B: Regulation of renal hydrogen excretion\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The net effect of these changes in cation distribution and renal function is that metabolic acidosis and relative hyperkalemia are often seen together.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Metabolic alkalosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;For similar reasons in which the above ionic changes are reversed, metabolic alkalosis and hypokalemia are commonly associated. Metabolic alkalosis causes potassium movement into the cells and hypokalemia causes hydrogen movement into the cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25891/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. With metabolic alkalosis, the plasma potassium concentration falls less than 0.4",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    per 0.1 unit increase in systemic pH [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25891/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Respiratory acid-base disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory acidosis and alkalosis induce relatively small changes in potassium balance [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25891/abstract/4\">",
"     4",
"    </a>",
"    ]. The reason for this minor effect is not well understood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CONCURRENT DISORDERS OF POTASSIUM BALANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding discussion has emphasized the effect of pH on potassium distribution between the cells and extracellular fluid. However, some patients have concurrent disorders of potassium balance that can affect this relationship. In particular, although metabolic acidosis typically produces relative hyperkalemia, patients may be hypokalemic at presentation if there is a source of potassium loss. Examples include diarrhea and renal tubular acidosis. On the other hand, true hyperkalemia (ie, increased body potassium stores) is present in patients with hypoaldosteronism (type 4 renal tubular acidosis) due to impaired urinary potassium excretion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=see_link\">",
"     \"Pathophysiology of renal tubular acidosis and the effect on potassium balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The situation may be more complicated in patients with diabetic ketoacidosis. These patients are often markedly potassium depleted because of urinary and gastrointestinal losses; however, hyperkalemia is found in approximately one-third of patients at presentation because of the hyperosmolality and insulin deficiency, not, as noted above, the metabolic acidosis. The administration of insulin typically leads to hypokalemia, unmasking the true state of potassium balance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15114?source=see_link\">",
"     \"Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5030212\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In metabolic acidosis, more than one-half of the excess hydrogen ions is buffered in the cells. In this setting, electroneutrality is maintained in part by the movement of intracellular potassium into the extracellular fluid (",
"      <a class=\"graphic graphic_figure graphicRef68866 \" href=\"UTD.htm?9/25/9628\">",
"       figure 1",
"      </a>",
"      ). Thus, metabolic acidosis results in a plasma potassium concentration that is elevated in relation to total body stores. The net effect in some cases is overt hyperkalemia. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Metabolic acidosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Just as metabolic acidosis can cause hyperkalemia, a rise in the plasma potassium concentration can induce a mild metabolic acidosis. This is due to transcellular exchange as most of the excess potassium enters the cells with intracellular hydrogen ions moving into the extracellular fluid. The net effect is an extracellular acidosis and an intracellular alkalosis. In the kidney, the intracellular alkalosis induced by hyperkalemia diminishes ammonium formation, thereby preventing excretion of the daily acid load and contributing to the metabolic acidosis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Metabolic acidosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For reasons that are similar but reciprocal, metabolic alkalosis and hypokalemia are commonly associated. Metabolic alkalosis causes potassium movement into the cells and hypokalemia causes hydrogen movement into the cells. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Metabolic alkalosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some patients with metabolic acid-base disorder have concurrent disorders of potassium balance which can produce hypokalemia or hyperkalemia through mechanisms other than those dependent upon cellular exchange. Examples include diarrhea, renal tubular acidosis, and diabetic ketoacidosis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Concurrent disorders of potassium balance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25891/abstract/1\">",
"      Aronson PS, Giebisch G. Effects of pH on potassium: new explanations for old observations. J Am Soc Nephrol 2011; 22:1981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25891/abstract/2\">",
"      Magner PO, Robinson L, Halperin RM, et al. The plasma potassium concentration in metabolic acidosis: a re-evaluation. Am J Kidney Dis 1988; 11:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25891/abstract/3\">",
"      Wiederseiner JM, Muser J, Lutz T, et al. Acute metabolic acidosis: characterization and diagnosis of the disorder and the plasma potassium response. J Am Soc Nephrol 2004; 15:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25891/abstract/4\">",
"      Adrogu&eacute; HJ, Madias NE. Changes in plasma potassium concentration during acute acid-base disturbances. Am J Med 1981; 71:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25891/abstract/5\">",
"      Fulop M. Serum potassium in lactic acidosis and ketoacidosis. N Engl J Med 1979; 300:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25891/abstract/6\">",
"      Graber M. A model of the hyperkalemia produced by metabolic acidosis. Am J Kidney Dis 1993; 22:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25891/abstract/7\">",
"      Adrogu&eacute; HJ, Chap Z, Ishida T, Field JB. Role of the endocrine pancreas in the kalemic response to acute metabolic acidosis in conscious dogs. J Clin Invest 1985; 75:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25891/abstract/8\">",
"      Adrogu&eacute; HJ, Madias NE. PCO2 and [K+]p in metabolic acidosis: certainty for the first and uncertainty for the other. J Am Soc Nephrol 2004; 15:1667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25891/abstract/9\">",
"      Altenberg GA, Aristimu&ntilde;o PC, Amorena CE, Taquini AC. Amiloride prevents the metabolic acidosis of a KCl load in nephrectomized rats. Clin Sci (Lond) 1989; 76:649.",
"     </a>",
"    </li>",
"    <li>",
"     Rose, BD, Post, TW, Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001, pp. 347-353.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25891/abstract/11\">",
"      Szylman P, Better OS, Chaimowitz C, Rosler A. Role of hyperkalemia in the metabolic acidosis of isolated hypoaldosteronism. N Engl J Med 1976; 294:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25891/abstract/12\">",
"      Sabatini S, Kurtzman NA. The maintenance of metabolic alkalosis: factors which decrease bicarbonate excretion. Kidney Int 1984; 25:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25891/abstract/13\">",
"      COOKE RE, SEGAR WE, CHEEK DB, et al. The extrarenal correction of alkalosis associated with potassium deficiency. J Clin Invest 1952; 31:798.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2353 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-8D13A6BE0D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_18_25891=[""].join("\n");
var outline_f25_18_25891=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5030212\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ACID-BASE DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Respiratory acid-base disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CONCURRENT DISORDERS OF POTASSIUM BALANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5030212\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2353\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2353|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/25/9628\" title=\"figure 1\">",
"      Acidosis and K distribution",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10089?source=related_link\">",
"      Chapter 11B: Regulation of renal hydrogen excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=related_link\">",
"      Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=related_link\">",
"      Pathophysiology of renal tubular acidosis and the effect on potassium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15114?source=related_link\">",
"      Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_18_25892="Cefpodoxime: Pediatric drug information";
var content_f25_18_25892=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cefpodoxime: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?26/44/27333?source=see_link\">",
"    see \"Cefpodoxime: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?11/6/11364?source=see_link\">",
"    see \"Cefpodoxime: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1046049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Cephalosporin (Third Generation)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1046042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/44/27333?source=see_link\">",
"      see \"Cefpodoxime: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants &ge;2 months and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Acute otitis media:",
"     </b>",
"     5 mg/kg/dose every 12 hours for 5 days; maximum dose: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Acute maxillary sinusitis:",
"     </b>",
"     5 mg/kg/dose every 12 hours for 10 days; maximum dose: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Pharyngitis/tonsillitis:",
"     </b>",
"     5 mg/kg/dose every 12 hours for 5-10 days; maximum dose: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adolescents and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Acute community-acquired pneumonia and bacterial exacerbations of chronic bronchitis:",
"     </b>",
"     200 mg every 12 hours for 14 days and 10 days, respectively",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Acute maxillary sinusitis:",
"     </b>",
"     200 mg every 12 hours for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Pharyngitis/tonsillitis:",
"     </b>",
"     100 mg every 12 hours for 5-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Skin and skin structure:",
"     </b>",
"     400 mg every 12 hours for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Uncomplicated gonorrhea (male and female) and rectal gonococcal infections (female):",
"     </b>",
"     200 mg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Uncomplicated urinary tract infection:",
"     </b>",
"     100 mg every 12 hours for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Administer every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemodialysis: Administer dose 3 times/week after hemodialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Not necessary in patient with cirrhosis",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F147748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Granules for suspension, oral: 50 mg/5 mL (50 mL, 100 mL); 100 mg/5 mL (50 mL, 100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 100 mg, 200 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F147732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1046053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet: Administer with food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension: May administer with or without food; shake suspension well before use",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1046046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Granules for suspension: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); after reconstitution, suspension may be stored in refrigerator for 14 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from light.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1046052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of susceptible acute, community-acquired pneumonia caused by",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     or nonbeta-lactamase producing",
"     <i>",
"      H. influenzae",
"     </i>",
"     (FDA approved in ages &ge;12 years and adults); alternative regimen for acute uncomplicated gonorrhea caused by",
"     <i>",
"      N. gonorrhoeae",
"     </i>",
"     (FDA approved in ages &ge;12 years and adults); uncomplicated skin and skin structure infections caused by",
"     <i>",
"      S. aureus",
"     </i>",
"     or",
"     <i>",
"      S. pyogenes",
"     </i>",
"     (FDA approved in ages &ge;12 years and adults); acute otitis media caused by",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     ,",
"     <i>",
"      S. pyogenes",
"     </i>",
"     ,",
"     <i>",
"      H. influenzae",
"     </i>",
"     , or",
"     <i>",
"      M. catarrhalis",
"     </i>",
"     (FDA approved in &ge;2 months to 12 years); pharyngitis or tonsillitis caused by",
"     <i>",
"      S. pyogenes",
"     </i>",
"     (FDA approved in ages &ge;2 months and adults); acute maxillary sinusitis caused by",
"     <i>",
"      H. influenzae",
"     </i>",
"     ,",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     , and",
"     <i>",
"      M. catarrhalis",
"     </i>",
"     (FDA approved in ages &ge;2 months and adults);and uncomplicated urinary tract infections caused by",
"     <i>",
"      E. coli",
"     </i>",
"     ,",
"     <i>",
"      Klebsiella",
"     </i>",
"     , and",
"     <i>",
"      Proteus",
"     </i>",
"     ; inactive against",
"     <i>",
"      Pseudomonas",
"     </i>",
"     and",
"     <i>",
"      Enterobacter",
"     </i>",
"     spp. (FDA approved in ages &ge;12 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F147815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Vantin may be confused with Ventolin&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F147813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Diaper rash, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Vaginal infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylaxis, anxiety, appetite decreased, chest pain, cough, dizziness, epistaxis, eye itching, fatigue, fever, flatulence, flushing, fungal skin infection, hypotension, insomnia, malaise, nightmares, pruritus, pseudomembranous colitis, purpuric nephritis, salivation decreased, taste alteration, tinnitus, vaginal candidiasis, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Reactions reported with other cephalosporins: Agranulocytosis, aplastic anemia, cholestasis, colitis, erythema multiforme, hemolytic anemia, hemorrhage, interstitial nephritis, toxic nephropathy, pancytopenia, renal dysfunction, seizure, serum-sickness reactions, Stevens-Johnson syndrome, superinfection, toxic epidermal necrolysis, urticaria, vaginitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1046056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cefpodoxime, any component, or cephalosporins",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1046041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with history of penicillin hypersensitivity, impaired renal function, and patients with a history of colitis; modify dosage in patients with renal impairment. Some formulations contain phenylalanine and must be avoided or used with caution in patients with phenylketonuria.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1046040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment. Do not use in patients with immediate-type hypersensitivity reactions to penicillin",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Suspension contains sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; use suspension containing sodium benzoate with caution in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F147741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of Cefpodoxime.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May decrease the absorption of Cefpodoxime. Separate oral doses by at least 2 hours.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Cephalosporins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1046058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food increases oral bioavailability",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F147744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5951646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic events were not observed in animal reproduction studies. An increase in most types of birth defects was not found following first trimester exposure to cephalosporins.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1046048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Observe patient for diarrhea; with prolonged therapy, monitor renal function periodically",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1046039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins; inhibits the final transpeptidation step of peptidoglycan synthesis resulting in cell wall death",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1046055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Tablet: Enhanced in the presence of food or low gastric pH",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Good tissue penetration, including lung and tonsils; penetrates into pleural fluid; poor penetration into CSF; small amounts appear in breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 22% to 33% (serum)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Following oral administration, cefpodoxime proxetil is de-esterified in the GI tract to the active metabolite, cefpodoxime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 2.2 hours (prolonged with renal impairment)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Within 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Primarily by the kidney with 29% to 33% of administered dose excreted unchanged in urine in 12 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Borin MT, &ldquo;A Review of the Pharmacokinetics of Cefpodoxime Proxetil,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1991, 42(Suppl 3):13-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/18/25892/abstract-text/1726203/pubmed\" id=\"1726203\" target=\"_blank\">",
"        1726203",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/18/25892/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fujii R, &ldquo;Clinical Trials of Cefpodoxime Proxetil Suspension in Pediatrics,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1991, 42(Suppl 3):57-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/18/25892/abstract-text/1726209 /pubmed\" id=\"1726209 \" target=\"_blank\">",
"        1726209",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mendelman PM, Del-Beccaro MA, McLinn SE, et al, &ldquo;Cefpodoxime Proxetil Compared With Amoxicillin-Clavulanate for the Treatment of Otitis Media,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1992, 121(3):459-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/18/25892/abstract-text/1517926/pubmed\" id=\"1517926\" target=\"_blank\">",
"        1517926",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13132 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-EE7AE732F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_18_25892=[""].join("\n");
var outline_f25_18_25892=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046049\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046042\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147748\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147732\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046053\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046046\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046052\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147815\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147813\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046056\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046041\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046040\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298993\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147741\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046058\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147744\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5951646\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046048\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046039\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046055\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13132\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13132|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/44/27333?source=related_link\">",
"      Cefpodoxime: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/6/11364?source=related_link\">",
"      Cefpodoxime: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_18_25893="Micropapillary ductal carcinoma in situ";
var content_f25_18_25893=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F58302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F58302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Micropapillary ductal carcinoma in situ",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of a specimen from the breast of a women with micropapillary ductal carcinoma in situ . The tumor cells form tufts which project into the lumen of the involved space. The nuclei are well differentiated (low grade).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stuart Schnitt, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_18_25893=[""].join("\n");
var outline_f25_18_25893=null;
var title_f25_18_25894="Lip anatomy";
var content_f25_18_25894=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F60055&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F60055&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lip anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 656px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Attia MW, Loiselle J. Management of soft-tissue injuries of the mouth. In: Textbook of Pediatric Emergency Procedures, 2nd Edition, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_18_25894=[""].join("\n");
var outline_f25_18_25894=null;
var title_f25_18_25895="Bullous pemphigoid eosinophilic spongiosis";
var content_f25_18_25895=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F79687&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F79687&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Bullous pemphigoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 295px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This hematoxylin and eosin stain of a skin tissue biopsy specimen from an early lesion of bullous pemphigoid demonstrates epidermal spongiosis, eosinophils within the epidermis, and a mixed perivascular cellular infiltrate in the upper dermis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Leiferman KM, Peters MS. Eosinophils in cutaneous diseases. In: Fitzpatrick's Dermatology in General Medicine, 8th ed, Goldsmith L, Katz S, Gilchrest B, et al (Eds), McGraw-Hill, New York 2012. Copyright &copy; 2012 McGraw-Hill Companies, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_18_25895=[""].join("\n");
var outline_f25_18_25895=null;
var title_f25_18_25896="Glioblastoma";
var content_f25_18_25896=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F67180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F67180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Glioblastoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 375px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dense cellularity, anaplastic nuclei, mitotic figures and necrosis with palisading of nuclei (left) in an astrocytic glioma are diagnostic of glioblastoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. David Louis.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_18_25896=[""].join("\n");
var outline_f25_18_25896=null;
var title_f25_18_25897="M leprae in skin during and after treatment";
var content_f25_18_25897=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F74309&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F74309&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 540px\">",
"   <div class=\"ttl\">",
"    Decline of Mycobacterium leprae in skin during and after treatment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 596px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Representative portions of sequential, annual biopsies of skin lesions from one lepromatous patient are shown, starting with the initial, pre-treatment biopsy (t = 0). The patient was treated with the National Hansens Disease Program recommended multidrug treatment (MDT) regimen of daily rifampin, dapsone, and clofazimine. Bacterial morphology had changed at 1 year; organisms are numerous but show evidence of degeneration. Treatment was discontinued at the time of the biopsy taken at 2 years. The bacterial load continued to decline slowly after MDT was discontinued, but rare organisms could still be observed after 6 years. Clinically, the cutaneous lesions resolved and did not relapse. (Fite stains, all at 1000x magnification.)",
"    <div class=\"footnotes\">",
"     * Treatment was stopped after 2 years.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_18_25897=[""].join("\n");
var outline_f25_18_25897=null;
var title_f25_18_25898="Treatment of the hypereosinophilic syndromes";
var content_f25_18_25898=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of the hypereosinophilic syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/18/25898/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/18/25898/contributors\">",
"     Florence Roufosse, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/18/25898/contributors\">",
"     Amy D Klion, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/18/25898/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/18/25898/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/18/25898/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/18/25898/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/18/25898/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/18/25898/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/18/25898/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hypereosinophilic syndromes (HES) are a group of disorders marked by the sustained overproduction of eosinophils, in which eosinophilic infiltration and mediator release cause damage to multiple organs. The decision to treat is based upon the patient's presentation as well as laboratory findings and the results of mutational analysis. Patients in urgent need of intervention include those with myeloproliferative HES, particularly those with mutations resulting in the fusion of the genes for Fip1-like1 (",
"    <em>",
"     FIP1L1",
"    </em>",
"    ) and platelet-derived growth factor receptor alpha (",
"    <em>",
"     PDGFRA",
"    </em>",
"    ), referred to as",
"    <span class=\"nowrap\">",
"     <em>",
"      FIP1L1/PDGFRA",
"     </em>",
"     -positive",
"    </span>",
"    disease. These patients typically have an extremely aggressive course with disabling complications and high mortality in the absence of treatment.",
"   </p>",
"   <p>",
"    The treatment and prognosis of HES will be reviewed here. The clinical features, pathophysiology, evaluation, and diagnosis of HES are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=see_link\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MONITORING AND GENERAL CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monitoring and general care involve an early trial of glucocorticoids alone in all patients",
"    <strong>",
"     except",
"    </strong>",
"    those with known",
"    <span class=\"nowrap\">",
"     <em>",
"      FIP1L1/PDGFRA",
"     </em>",
"     -associated",
"    </span>",
"    disease without cardiac involvement, as well as vigilance for the complications of HES.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Monitoring for organ involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;End-organ involvement may develop insidiously and is not correlated with the degree of blood eosinophilia. Therefore, all patients, including those who are asymptomatic, should undergo screening for organ involvement at six-month intervals, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood chemistries (including hepatic enzymes, renal function, and troponin)",
"     </li>",
"     <li>",
"      Electrocardiogram and echocardiogram",
"     </li>",
"     <li>",
"      Pulmonary function tests",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional testing should be based upon symptoms and prior evidence of organ involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Vigilance for thrombotic complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombotic and thromboembolic events are a major cause of morbidity among patients with HES, and a high degree of suspicion for these complications must be maintained. The available series suggest that about one-quarter of patients with HES develop thromboembolic complications [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. These complications are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=see_link&amp;anchor=H17#H17\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes\", section on 'Thrombotic complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prophylactic use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antiplatelet agents are",
"    <strong>",
"     NOT",
"    </strong>",
"    currently recommended in the absence of documented thrombi, in part because the effectiveness of these interventions is unclear. Recurrent thrombotic events have occurred in adequately anticoagulated HES patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Anticoagulation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Planning for disease progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early HLA typing for possible allogeneic hematopoietic cell transplantation should be considered for patients with any of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <em>",
"        FIP1L1/PDGFRA",
"       </em>",
"       -associated",
"      </span>",
"      HES",
"     </li>",
"     <li>",
"      Cytogenetic abnormalities",
"     </li>",
"     <li>",
"      Potentially life-threatening end-organ involvement (especially cardiac or CNS involvement)",
"     </li>",
"     <li>",
"      Features of myeloproliferative disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Hematopoietic cell transplant'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ACUTE REDUCTION OF VERY SEVERE EOSINOPHILIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In rare instances, patients may present with extremely elevated eosinophil levels (eg, above 100,000",
"    <span class=\"nowrap\">",
"     cells/microliter)",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     signs/symptoms",
"    </span>",
"    of hyperleukocytosis. In these situations, hypercellularity should be rapidly reduced. High dose intravenous glucocorticoids (eg, at a dose equivalent to 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) may be administered. Important tests to exclude other disorders in the differential diagnosis that can be obtained within a few hours should be performed, although glucocorticoid therapy should not be delayed for this purpose. Hyperleukocytosis is reviewed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19576?source=see_link\">",
"     \"Hyperleukocytosis and leukostasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=see_link&amp;anchor=H31#H31\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We would suggest obtaining blood for the following studies before initiating urgent therapy: complete blood count and differential, chemistry panel, vitamin B12, IgE, IgM, IgG, serum tryptase, antineutrophil cytoplasmic antibodies, lymphocyte phenotyping,",
"    <span class=\"nowrap\">",
"     <em>",
"      FIP1L1/PDGFRA",
"     </em>",
"    </span>",
"    mutational analysis, studies for",
"    <span class=\"nowrap\">",
"     <em>",
"      BCR/ABL",
"     </em>",
"     ,",
"    </span>",
"    plus samples for DNA and extra serum to be used in further testing once the patient is stabilized. If possible, a bone marrow aspirate and biopsy should be performed prior to the administration of high dose glucocorticoids, since glucocorticoids can alter the interpretation of these studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=see_link&amp;anchor=H23#H23\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes\", section on 'Evaluation and diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In response to high dose glucocorticoids, the eosinophil count typically either remains the same or drops dramatically (eg, by more than 50 percent of the original value). If a significant reduction is not observed after 24 hours, then glucocorticoids alone are unlikely to be effective for that patient.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other interventions that have been used to reduce eosinophil counts acutely in a small number of cases include the cytoreductive agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      mesylate, and leukapheresis.",
"     </li>",
"     <li>",
"      In this setting,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      has been administered at doses of 1 to 2",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      intravenously, weekly to monthly [",
"      <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/5\">",
"       5",
"      </a>",
"      ]. In responsive patients, eosinophil counts begin to fall within hours.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       Imatinib",
"      </a>",
"      therapy (400 mg daily) may be effective in steroid-refractory patients with extremely high counts, since these patients are more likely to have",
"      <span class=\"nowrap\">",
"       <em>",
"        FIP1L1/PDGFRA",
"       </em>",
"       -positive",
"      </span>",
"      disease. It is relatively less toxic than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      , although it may take longer (two to four weeks) to reduce counts and must be administered in conjunction with glucocorticoids in patients with evidence of cardiac involvement. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Caution in patients with cardiac disease'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     OVERVIEW OF PHARMACOLOGIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pharmacologic management of HES is initiated with glucocorticoids, the tyrosine kinase inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , or in some cases, the combination of both agents. The choice of the initial therapeutic agent or agents for a given patient depends mainly on the presence or absence of the",
"    <em>",
"     FIP1L1-PDGFRA",
"    </em>",
"    fusion or clinical features of chronic eosinophilic leukemia. Treatment of resistant or recurrent disease may involve several agents, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    and other chemotherapeutic agents, interferon-alfa, anti-IL-5, and anti-CD52. Allogeneic hematopoietic cell transplantation is an option for patients who have failed pharmacologic therapy.",
"   </p>",
"   <p>",
"    The goals of therapy are to reduce the signs and symptoms of eosinophilic disease, to maintain the eosinophil count below",
"    <span class=\"nowrap\">",
"     1500/mm3,",
"    </span>",
"    and in doing so, to prevent progression of end organ dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT OF PDGFRA-POSITIVE HES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first-line therapy for all patients with",
"    <em>",
"     PDGFRA",
"    </em>",
"    -positive disease is the tyrosine kinase inhibitor,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    mesylate. Treatment should be initiated promptly, as soon as the diagnosis is established, to prevent progression of cardiac disease and other severe end organ damage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Imatinib mesylate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     Imatinib",
"    </a>",
"    mesylate is a potent inhibitor of abl, c-kit, PDGFRA, and PDGFRB kinase activity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. It induces disease remission and prevents progression of disease. Patients with potential cardiac disease, as assessed by elevated serum troponin levels",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    abnormalities on echocardiography, should receive concomitant glucocorticoids when therapy with imatinib is initiated to prevent acute necrotizing myocarditis. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Caution in patients with cardiac disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Studies have demonstrated clinical, hematological, and molecular remission in the majority of patients with",
"    <span class=\"nowrap\">",
"     <em>",
"      FIP1L1/PDFGRA",
"     </em>",
"     -associated",
"    </span>",
"    HES [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/6,8-15\">",
"     6,8-15",
"    </a>",
"    ]. Clinical symptoms resolve and eosinophil counts normalize, generally within one to two weeks. In contrast, cardiac symptoms due to structural abnormalities resulting from endomyocardial fibrosis, and fixed neurological deficits may not improve with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/11,16,17\">",
"     11,16,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one prospective multicenter study of 72 Italian patients with idiopathic or primary HES, 63 were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      , 100 to 400",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/15\">",
"       15",
"      </a>",
"      ]. Of the 63 male patients, 27 carried the",
"      <em>",
"       FIP1L1-PDGFRA",
"      </em>",
"      rearrangement. These 27 achieved a complete hematologic remission and remained in remission at the time of publication (median follow-up of 25 months). Treatment was continued indefinitely at doses of 100 to 400",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"     <li>",
"      An elevated serum tryptase level (&gt;11.5",
"      <span class=\"nowrap\">",
"       ng/mL)",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      markedly elevated serum B12 level (&gt;2000",
"      <span class=\"nowrap\">",
"       pg/mL)",
"      </span>",
"      appear to be markers for the presence of the",
"      <span class=\"nowrap\">",
"       <em>",
"        FIP1L1/PDGFRA",
"       </em>",
"      </span>",
"      mutation in HES, and may be useful in situations where gene testing is not available. In one study of 15 patients with HES, nine had mildly elevated serum tryptase levels and other features of myeloproliferative disease including elevated serum B12 levels, dysplastic eosinophils, and splenomegaly [",
"      <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/10\">",
"       10",
"      </a>",
"      ]. Six of the patients with elevated tryptase were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      with sustained clinical and hematologic response. Five of these nine patients were subsequently tested for the abnormal fusion tyrosine kinase, and all were found to be positive, whereas none of the four patients with HES and normal serum tryptase levels had the abnormal protein.",
"     </li>",
"     <li>",
"      In the retrospective series of 188 patients previously mentioned, 17 patients had the",
"      <span class=\"nowrap\">",
"       <em>",
"        FIP1L1/PDGFRA",
"       </em>",
"      </span>",
"      mutation, and all were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/18\">",
"       18",
"      </a>",
"      ]. All but two had a complete response. Of note, serum tryptase levels were normal in two patients with a documented",
"      <span class=\"nowrap\">",
"       <em>",
"        FIP1L1/PDGFRA",
"       </em>",
"       -mutation;",
"      </span>",
"      whereas, the serum B12 level was markedly elevated (&gt;2000",
"      <span class=\"nowrap\">",
"       pg/mL)",
"      </span>",
"      in all",
"      <span class=\"nowrap\">",
"       <em>",
"        FIP1L1/PDGFRA",
"       </em>",
"       -positive",
"      </span>",
"      patients, suggesting that serum B12 levels may be a more sensitive marker for this disorder.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The",
"    <em>",
"     FIP1L1-PDGFRA",
"    </em>",
"    fusion is exquisitely sensitive to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , and doses required to induce molecular remission are lower than those used for treating chronic myeloid leukemia (CML). Thus, dose-related side effects, such as myalgia and peripheral edema, are uncommon in patients with HES. However, serious complications have been reported, including neutropenia and life-threatening myocarditis (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Caution in patients with cardiac disease'",
"    </a>",
"    below.) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/9,14,16\">",
"     9,14,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     Imatinib",
"    </a>",
"    is a potential teratogen and issues regarding family planning should be discussed with men and women taking imatinib. (See",
"    <a class=\"local\" href=\"#H3133669\">",
"     'Family planning'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Primary resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    in patients with the",
"    <span class=\"nowrap\">",
"     <em>",
"      FIP1L1/PDGFRA",
"     </em>",
"    </span>",
"    mutation is uncommon, but has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/19\">",
"     19",
"    </a>",
"    ]. In one patient, two point mutations were detected in the",
"    <em>",
"     PDGFRA",
"    </em>",
"    domain, the functional significance of which has not yet been explored [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/20\">",
"     20",
"    </a>",
"    ]. Secondary resistance is discussed below (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Imatinib-resistant disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Understanding of the most appropriate dose and duration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    therapy is evolving. Doses of imatinib as low as 100 mg daily (or even weekly) are effective in controlling the eosinophilia and clinical symptoms in most patients with the",
"    <span class=\"nowrap\">",
"     <em>",
"      FIP1L1/PDGFRA",
"     </em>",
"    </span>",
"    mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/21-23\">",
"     21-23",
"    </a>",
"    ], although higher doses are often necessary in",
"    <span class=\"nowrap\">",
"     <em>",
"      FIP1L1/PDGFRA",
"     </em>",
"     -negative",
"    </span>",
"    patients. However, molecular evidence of the",
"    <span class=\"nowrap\">",
"     <em>",
"      FIP1L1/PDGFRA",
"     </em>",
"    </span>",
"    mutation may persist on low dose therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/14,24\">",
"     14,24",
"    </a>",
"    ]. Experience with imatinib in the treatment of CML suggests that clinical relapse is more common in patients with detectable residual disease, and so initiating therapy at a higher dose (400 mg daily) may be preferred. Therefore, we suggest an initial oral dose of 400",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Caution in patients with cardiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     Imatinib",
"    </a>",
"    is generally well-tolerated, as mentioned previously. However, patients with HES and cardiac involvement, as assessed by echocardiographic evidence of myocarditis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    elevated serum troponin levels, may be at risk for left ventricular dysfunction and cardiogenic shock when imatinib treatment is initiated. Presumably, the mechanism involves massive release of eosinophil granule proteins and subsequent damage to the myocardium, although this has not been conclusively demonstrated. Cardiac damage was reportedly reversible with prompt institution of systemic glucocorticoids, intensive support, and discontinuation of imatinib [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/9,16\">",
"     9,16",
"    </a>",
"    ]. Therefore, concomitant treatment with systemic glucocorticoids (1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily) for one to two weeks when imatinib is initiated is recommended for patients with any evidence of cardiac involvement (even limited to asymptomatic elevations in troponin levels) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3133669\">",
"    <span class=\"h3\">",
"     Family planning",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a paucity of data regarding the risk of teratogenicity and pregnancy loss associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    use. The majority of data comes from the use of imatinib in the setting of chronic myeloid leukemia (CML). Men and women taking imatinib are advised to take measures to avoid pregnancy or exposure of a developing fetus to imatinib. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27290?source=see_link&amp;anchor=H21#H21\">",
"     \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\", section on 'Pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Preclinical studies have reported teratogenicity of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    in some animals, but not others [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/25\">",
"     25",
"    </a>",
"    ]. Human case reports have described significant congenital abnormalities in the offspring of some women treated with imatinib [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/26\">",
"     26",
"    </a>",
"    ]. Women of childbearing potential taking imatinib have been advised not to become pregnant and that effective contraception, preferably barrier, should be used to prevent pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/27\">",
"     27",
"    </a>",
"    ]. Women taking imatinib are also advised to avoid breastfeeding. Whether imatinib therapy will affect future fertility in women is unknown. Primary ovarian insufficiency associated with imatinib therapy has been described in a case report [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no data to suggest adverse effects on pregnancy outcome when the father is taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , and successful pregnancies have been described involving men taking imatinib for CML [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/27,29\">",
"     27,29",
"    </a>",
"    ]. Temporary cessation of imatinib therapy in men attempting to conceive a child may result in the emergence of a more resistant clone. Experience in clinical trials and anecdotal reports have generally not shown evidence for reduced sperm counts or infertility in males taking imatinib for CML [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/25\">",
"     25",
"    </a>",
"    ]. However, a case report has described oligospermia in a patient receiving imatinib for HES [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/30\">",
"     30",
"    </a>",
"    ]. Since most patients with",
"    <span class=\"nowrap\">",
"     <em>",
"      FIP1L1/PDGFRA",
"     </em>",
"     -associated",
"    </span>",
"    HES are young men who will be receiving treatment long term, sperm banking",
"    <strong>",
"     before",
"    </strong>",
"    the initiation of therapy should be considered.",
"   </p>",
"   <p>",
"    Advice for patients who have become pregnant despite the above recommendations is difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/27\">",
"     27",
"    </a>",
"    ]. For women, continuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    may result in damage to the developing fetus, while its discontinuation may result in disease relapse in the mother. In some cases, couples have decided on therapeutic termination of the pregnancy, others have continued treatment throughout the pregnancy, while others have discontinued imatinib and were treated with other agents (eg, interferon) during the remainder of the pregnancy, with reinstitution of imatinib following delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/26,31\">",
"     26,31",
"    </a>",
"    ]. For men taking imatinib whose partners become pregnant, the evidence is even less clear. It is unknown how much exposure to imatinib may be provided to the fetus through sexual encounters between a man taking imatinib and his pregnant partner. However, it seems prudent for men pursuing a sexually active relationship with a pregnant partner to use barrier protection (ie, condoms) in order to limit exposure of the developing fetus to imatinib.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typically, symptoms improve and eosinophil counts normalize within one to two weeks after initiation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    . Thereafter, the dose is reduced to the lowest effective dose that maintains suppression of PCR-detectable",
"    <span class=\"nowrap\">",
"     <em>",
"      FIP1L1/PDGFRA",
"     </em>",
"    </span>",
"    transcript levels, as well as blood eosinophilia, and continues indefinitely [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/12,24\">",
"     12,24",
"    </a>",
"    ]. Reducing or stopping imatinib in patients with the",
"    <span class=\"nowrap\">",
"     <em>",
"      FIP1L1/PDGFRA",
"     </em>",
"    </span>",
"    mutation has resulted in a rapid return of",
"    <span class=\"nowrap\">",
"     <em>",
"      FIP1L1/PDGFRA",
"     </em>",
"    </span>",
"    transcripts, detected by polymerase chain reaction (PCR) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/24\">",
"     24",
"    </a>",
"    ]. A number of studies have demonstrated that imatinib is not effective in eliminating the early progenitor cells in CML. Extrapolating these results to HES, it is likely that lifelong imatinib therapy will be required for most patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7034?source=see_link&amp;anchor=H4#H4\">",
"     \"Initial treatment of chronic myeloid leukemia in chronic phase\", section on 'Imatinib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Imatinib-resistant disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few cases of acquired resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    among",
"    <span class=\"nowrap\">",
"     <em>",
"      FIP1L1/PDGFRA",
"     </em>",
"     -positive",
"    </span>",
"    patients have been reported. These were associated with a single base (T6741) substitution in the imatinib-binding portion of the kinase, similar to the T3151 mutation in",
"    <em>",
"     ABL",
"    </em>",
"    described in imatinib-resistant CML [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/6,14\">",
"     6,14",
"    </a>",
"    ]. The best approach to managing patients with acquired imatinib resistance has not been extensively studied, although options include use of other tyrosine kinase inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    ) or hematopoietic cell allogeneic transplantation (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Hematopoietic cell transplant'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Other tyrosine kinase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    is currently the only commercially available tyrosine kinase inhibitor with proven activity in HES, several new agents with activity against PDGFR, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    , are available for other clinical uses [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/6,32-34\">",
"     6,32-34",
"    </a>",
"    ]. Nilotinib and sorafenib have each shown efficacy in single case reports of imatinib-resistant HES [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/35,36\">",
"     35,36",
"    </a>",
"    ], although the duration of response in the patient treated with sorafenib was short-lived. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41225?source=see_link&amp;anchor=H15#H15\">",
"     \"Overview of the treatment of chronic myeloid leukemia\", section on 'Treatment of disease resistance or drug intolerance'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27290?source=see_link\">",
"     \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT OF OTHER FORMS OF HES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all patients with HES require treatment at the time of diagnosis. Asymptomatic patients should be assessed periodically for end-organ involvement. Therapy is indicated for symptomatic patients or those with evidence of developing end organ damage. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Monitoring for organ involvement'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Glucocorticoids are the initial therapy of choice for patients with organ involvement who do",
"    <strong>",
"     NOT",
"    </strong>",
"    have the",
"    <em>",
"     FIP1L1-PDGFRA",
"    </em>",
"    fusion or another",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    -sensitive tyrosine kinase mutation. Second-line therapies are used for patients whose disease has not responded to glucocorticoids, or in combination with glucocorticoids as steroid-sparing agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    at doses of 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily or 60 mg once daily for one to two weeks is the primary therapy for",
"    <em>",
"     FIP1L1-PDGFRA",
"    </em>",
"    -negative HES. In a large series of 188 HES patients, 141 (75 percent) received glucocorticoids alone as initial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/18\">",
"     18",
"    </a>",
"    ]. In the absence of evidence for organ involvement (ie, the presence of isolated cutaneous or soft tissue manifestations), starting with a lower dose (20 to 30 mg daily) may be contemplated. Strongyloides infection should be excluded in patients with a potential exposure history, prior to initiation of glucocorticoids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24745?source=see_link&amp;anchor=H12#H12\">",
"     \"Approach to the patient with eosinophilia\", section on 'Parasitic infections'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the eosinophil count does not respond to this initial dose, even higher doses (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , 1 gram daily or 15",
"    <span class=\"nowrap\">",
"     mg/kg/day)",
"    </span>",
"    could be administered for a few days, as some patients may require very high doses initially. However, this dose is too toxic for extended use, and alternative steroid-sparing regimens should be planned.",
"   </p>",
"   <p>",
"    Once blood eosinophilia is suppressed and symptoms are controlled, daily doses are gradually reduced to an alternate day schedule of the lowest dose that maintains control of the eosinophil count and clinical manifestations. In the large series mentioned previously, patients were able to reduce the dose of glucocorticoids to a median dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    of 10 mg per day [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The tapering schedule is highly variable, and should be guided by the severity of the presenting clinical complications and the extent to which eosinophil suppression has been achieved by treatment. Doses can be tapered more rapidly in patients with complications that are not life-threatening and in those whose eosinophil levels plummet dramatically after initiation of glucocorticoids. Eosinophil levels and clinical manifestations should be monitored weekly at the beginning of therapy, changing to progressively longer intervals, depending on the response.",
"   </p>",
"   <p>",
"    Glucocorticoids appear to be highly effective at treating most patients with HES. In the large series mentioned before, partial or complete remission was achieved in 85 percent at one month [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although most patients will respond temporarily to high doses of glucocorticoids, there are subgroups of patients that are most likely to have sustained improvement, including those with the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prolonged eosinopenic response after a single dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"     </li>",
"     <li>",
"      Very high serum levels of serum thymus and activation-regulated chemokine (TARC) (ie, &gt;10,000",
"      <span class=\"nowrap\">",
"       pg/mL)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/18\">",
"       18",
"      </a>",
"      ], although a threshold level for predicting glucocorticoid responsiveness has not been established",
"     </li>",
"     <li>",
"      Angioedema",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      urticaria",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mechanism of action of glucocorticoids in HES is not entirely clear. Glucocorticoids interfere with eosinophilopoiesis, but this is unlikely to account for the observation that eosinopenia may occur as early as four hours after glucocorticoid administration [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/37\">",
"     37",
"    </a>",
"    ]. Accelerated apoptosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sequestration of eosinophils may also play a role [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/38\">",
"     38",
"    </a>",
"    ]. Although a small number of steroid-refractory patients appear to have decreased glucocorticoid receptor expression [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/39\">",
"     39",
"    </a>",
"    ], the mechanisms of glucocorticoid resistance in most patients with HES have not been defined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Addition of steroid-sparing agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a stable maintenance dose of glucocorticoids has been reached, the dose may be reduced further by introducing a second steroid-sparing agent, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    , interferon-alpha, or anti-IL-5. A corticosteroid-sparing agent is indicated if the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    dose exceeds 10",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    or in the presence of significant side effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Each of these agents is discussed in the next section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Second-line therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other agents are used in the management of HES, either as second-line monotherapy for",
"    <span class=\"nowrap\">",
"     <em>",
"      FIP1L1/PDGFRA",
"     </em>",
"     -negative",
"    </span>",
"    HES that has not responded to glucocorticoids, or in combination with glucocorticoids as steroid-sparing agents. The most frequently used are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    and interferon-alfa. Anti-IL-5 and anti-CD52 are more novel therapies in which there is growing interest.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     Imatinib",
"    </a>",
"    has been used as an alternative first-line agent in some patients with a negative test for the",
"    <span class=\"nowrap\">",
"     <em>",
"      FIP1L1/PDGFRA",
"     </em>",
"    </span>",
"    mutation, although preliminary data suggest that this is not effective in most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A choice of second-line therapy is primarily based upon disease characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with abnormal clonal T cells (L-HES), we suggest the addition of interferon-alpha to glucocorticoid therapy. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Interferon alfa'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For patients with myeloproliferative features in the absence of the",
"      <span class=\"nowrap\">",
"       <em>",
"        FIP1L1/PDGFRA",
"       </em>",
"      </span>",
"      rearrangement who do NOT respond to glucocorticoids, we suggest a trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      . This should be added to glucocorticoids in patients with potential cardiac disease, as assessed by elevated serum troponin levels",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      abnormalities on echocardiography (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Imatinib'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For other patients with HES (excluding those with L-HES or myeloproliferative features), we suggest either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      or interferon alfa as the second-line agent. Although response rates appear to be slightly higher with interferon alpha, side effects are generally less with hydroxyurea [",
"      <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/18\">",
"       18",
"      </a>",
"      ]. Thus, either drug is a reasonable second-line agent. The choice of therapy should be individualized, taking into account the side effect profiles, cost, and patient preference (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Hydroxyurea'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Hydroxyurea",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     Hydroxyurea",
"    </a>",
"    is the preferred second-line agent for many patients with HES (excluding those with L-HES or myeloproliferative features), due to its side effect profile, low cost, and efficacy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     Hydroxyurea",
"    </a>",
"    is usually added to glucocorticoids if steroid toxicity has become dose-limiting, or less commonly, used as monotherapy when glucocorticoids have failed [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/18\">",
"     18",
"    </a>",
"    ]. It is administered orally at an initial dose of 500 to 1000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and increased to 2000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    as tolerated. Hydroxyurea has relatively few side effects compared to other chemotherapeutic agents, although hematological toxicity and gastrointestinal side effects may become issues at higher doses [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Patients should use contraception because hydroxyurea is a teratogen. In HES, this agent is usually given in combination with other agents.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one prospective study, combined therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      (2000 mg per day) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       mg/kg/day)",
"      </span>",
"      was administered to 18 patients with",
"      <span class=\"nowrap\">",
"       <em>",
"        FIP1L1/PDGFRA",
"       </em>",
"       -negative",
"      </span>",
"      HES, except for three patients who were refractory to glucocorticoid therapy prior to the trial [",
"      <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/42\">",
"       42",
"      </a>",
"      ]. Among the 15 patients treated with this combination, nine had a complete response, and six had a partial response. After an initial response was observed, doses were tapered progressively, and in most patients, disease was controlled with low-dose hydroxyurea (500 to 1000 mg daily) as a single agent.",
"     </li>",
"     <li>",
"      In the series of 188 patients, 36 patients were treated with the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      and glucocorticoids, and 25 (69 percent) responded [",
"      <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/18\">",
"       18",
"      </a>",
"      ]. Of those 18 patients treated with hydroxyurea alone, 13 responded partially or completely.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another study found that low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    potentiated the effect of interferon alfa in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Interferon alfa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interferon alfa (IFNa), administered",
"    <strong>",
"     as a single agent,",
"    </strong>",
"    is an acceptable alternative second-line therapy to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    for patients with HES who do not respond to glucocorticoids. IFNa is also used in concert with glucocorticosteroids as a glucocorticoid-sparing agent in those who require higher doses of glucocorticoids. IFNa",
"    <strong>",
"     monotherapy",
"    </strong>",
"    is",
"    <strong>",
"     not",
"    </strong>",
"    recommended in HES patients with the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with abnormal clonal T cells (L-HES): IFNa prevented spontaneous apoptosis in vitro of phenotypically abnormal clonal T cells isolated from peripheral blood of two patients with L-HES [",
"      <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/44\">",
"       44",
"      </a>",
"      ]. Since this could theoretically lead to expansion of the abnormal clonal population, it has been suggested that IFNa as monotherapy should be avoided in patients with lymphocytic variant disease, although it may be used in combination with glucocorticoids [",
"      <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/45\">",
"       45",
"      </a>",
"      ]. Instead, these patients should be initially treated with glucocorticoids. If disease is resistant or side effects of glucocorticoids are excessive, then IFNa may be added. There is no evidence that patients with L-HES respond to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      .",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       Hydroxyurea",
"      </a>",
"      , through its central effects on eosinophilopoiesis, may decrease eosinophil levels, but should only be considered in patients who do not respond to, or cannot tolerate, IFNa.",
"     </li>",
"     <li>",
"      Patients with myeloproliferative variants of HES: For these patients,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      provides a less toxic alternative to IFNa and targets a molecular defect underlying the hypereosinophilia. Therefore, a short trial of imatinib should be instituted before IFNa use is contemplated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mechanism of action of IFNa in HES has not been fully elucidated, although it may involve inhibition of eosinophil differentiation and proliferation, and inhibition of Th2 differentiation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interferon alfa (IFNa) has been effective in a number of small case series [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/48-52\">",
"     48-52",
"    </a>",
"    ]. In the series of 188 patients, 46 patients received IFNa, most with glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/18\">",
"     18",
"    </a>",
"    ]. Response rates to combination therapy and monotherapy were 75 and 50 percent, respectively. However, most eventually stopped IFNa, due to either intolerance (50 percent) or lack of efficacy (36 percent).",
"   </p>",
"   <p>",
"    Doses of IFNa that have been utilized in the treatment of HES range from one million to eight million units per dose, three to seven times weekly, administered subcutaneously. Most patients respond to a total weekly dose between 7 and 14 million units. Although the optimal schedule for administration has not been studied, a sample approach is to initiate treatment with one to two million units per injection on alternate days. If this is tolerated, the dose can be increased by 0.5 to 1 million units per injection, gradually increasing to three to four million units per injection, three times weekly. It may take several weeks to reach the effective dose and then to observe a response. Delayed effects on eosinophil levels and symptoms are related both to the mechanisms of action and poor initial tolerance.",
"   </p>",
"   <p>",
"    Pegylated interferon (peginterferon) (1.5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    once weekly) has been used in a small number of cases and appears to be equivalent to standard interferon therapy in efficacy and side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/48\">",
"     48",
"    </a>",
"    ]. Peginterferon effectively controlled eosinophilia and disease manifestations in six patients with HES, four of whom were switched over from treatment with recombinant IFNa, and two of whom had not received prior interferon therapy. Clinical remission was maintained despite progressive dose reduction after disease stabilization, and in four of six patients, the interval between injections could be extended to 10 to 15 days [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/53\">",
"     53",
"    </a>",
"    ]. The authors reserve peginterferon for patients with stable disease on standard interferon therapy.",
"   </p>",
"   <p>",
"    Side effects of IFNa include dose-dependent flu-like symptoms, depression, peripheral neuropathy, fatigue, thyroid dysfunction, induction of auto-antibodies, and increased liver transaminases. The dose should be reduced if cytopenias develop. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27111?source=see_link&amp;anchor=H3#H3\">",
"     \"Interferon alpha for the treatment of chronic myeloid leukemia\", section on 'Toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Anti-IL-5",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preparations of anti-interleukin (IL)-5 antibodies have shown promising results in the treatment of",
"    <span class=\"nowrap\">",
"     <em>",
"      FIP1L1/PDGFRA",
"     </em>",
"     -negative",
"    </span>",
"    HES patients, but are available only in clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/54-60\">",
"     54-60",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    Mepolizumab, a humanized anti-IL-5 antibody, was evaluated as a glucocorticoid sparing agent in a randomized multicenter trial of 85 HES patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/55\">",
"     55",
"    </a>",
"    ]. All patients were negative for the",
"    <span class=\"nowrap\">",
"     <em>",
"      FIP1L1/PDGFRA",
"     </em>",
"    </span>",
"    fusion gene and disease was controlled on glucocorticoid monotherapy at doses equivalent to 20 to 60 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    per day. All but three patients had undetectable levels of serum IL-5, perhaps due to suppression by glucocorticoids. Patients were randomly assigned to receive either mepolizumab (750 mg intravenously every four weeks, for nine doses) or placebo (saline). Tapering of glucocorticoids was attempted in all subjects, according to a predefined protocol requiring eosinophil counts",
"    <span class=\"nowrap\">",
"     &lt;750/microL",
"    </span>",
"    and no new or worsening symptoms. The primary endpoint was a reduction of the glucocorticoid dose that was significant and durable, and was defined as 10 mg of prednisone daily or less, for at least eight consecutive weeks. An open-label extension of this trial did not identify any safety concerns in 78 subjects who received therapy for a mean duration of 251 weeks (range 4 to 302 weeks) and confirmed the efficacy of mepolizumab as a long-term steroid-sparing agent in HES [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who received mepolizumab had the following outcomes when compared with patients who received placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/55\">",
"     55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Higher rates of glucocorticoid independence (46 versus 5 percent, respectively). Responders included patients with respiratory, cardiac, gastrointestinal, musculoskeletal, and neurological manifestations of HES, while patients with cutaneous manifestations appeared to benefit less.",
"     </li>",
"     <li>",
"      Higher rates of treatment-related adverse events (37 versus 29 percent, respectively). One patient with severe HES associated with preexisting cardiovascular comorbidities receiving mepolizumab died from cardiac arrest deemed unrelated to the study treatment. Elevations in gamma-glutamyltransferase were seen in 5 percent of mepolizumab patients and none of the controls, although this difference was not statistically significant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An investigator-based exploratory study was conducted on patients enrolled in the placebo-controlled trial, to determine whether patients with L-HES had similar response rates to mepolizumab compared to those with undefined HES [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/62\">",
"     62",
"    </a>",
"    ]. The ability to taper corticosteroids on mepolizumab was similar in patients with L-HES and those with a normal T-cell profile, although a lower proportion of L-HES patients maintained eosinophil levels below",
"    <span class=\"nowrap\">",
"     600/microL.",
"    </span>",
"    Similarly, increased serum TARC levels (&gt;1000",
"    <span class=\"nowrap\">",
"     pg/mL)",
"    </span>",
"    had no significant impact on the ability to reduce corticosteroid doses, although a lower proportion of patients with elevated TARC achieved eosinophil control on mepolizumab.",
"   </p>",
"   <p>",
"    These results suggest that anti-IL-5 therapy is useful as a glucocorticoid sparing agent. In addition, the finding that 14 percent of patients receiving placebo could also reduce their",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    dose significantly by the end of the study suggests that additional glucocorticoid tapering should be attempted in all patients in whom the disease has been previously stabilized with glucocorticoid therapy.",
"   </p>",
"   <p>",
"    Other smaller uncontrolled studies have examined the use of mepolizumab or reslizumab (Cephalon Therapeutics) in HES patients refractory to other therapies, or in patients with elevated serum levels of IL-5 at baseline, with mostly favorable results [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/54,57-59\">",
"     54,57-59",
"    </a>",
"    ]. However, mepolizumab is available on a case by case basis for compassionate use, and reslizumab is not currently available for use in HES.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Anti-CD52",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eosinophils express surface CD52, a protein targeted by the anti-CD52 antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    . A trial of alemtuzumab in patients with",
"    <span class=\"nowrap\">",
"     <em>",
"      FIP1L1/PDGFRA",
"     </em>",
"     -negative",
"    </span>",
"    HES reported that eosinophil counts normalized at a median time of two weeks (range: 0.5 to 5 weeks) in 10 of 11 patients refractory to various therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. The median duration of remission was three months; 7 of the 10 patients achieving remission relapsed, five while off therapy. Two patients achieved a second remission upon rechallenge with alemtuzumab.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     Alemtuzumab",
"    </a>",
"    , which also targets T cells, was shown to be effective treatment for a patient with L-HES associated with a CD3-CD4+ T cell subset in one case report [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/65\">",
"     65",
"    </a>",
"    ]. Potential side effects include profound hematologic toxicity with immunosuppression, leading to an increased risk of opportunistic infections, namely CMV reactivation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30442?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of relapsed or refractory chronic lymphocytic leukemia\", section on 'Alemtuzumab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Imatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with HES and features of myeloproliferative disease have responded to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    despite a negative test for the",
"    <span class=\"nowrap\">",
"     <em>",
"      FIP1L1/PDGFRA",
"     </em>",
"    </span>",
"    mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/6,40,66\">",
"     6,40,66",
"    </a>",
"    ]. These individuals demonstrate bone marrow findings consistent with chronic myeloproliferative disease, and in some cases, have been found to have mutations involving",
"    <em>",
"     PDGFRA",
"    </em>",
"    or",
"    <em>",
"     PDGFRB",
"    </em>",
"    with other fusion partners [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Since testing for these alternative mutations is not widely available, imatinib therapy may be considered for first-line therapy in patients presenting with HES and features of myeloproliferative disease (ie, after an initial",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    challenge, but before any other therapeutic intervention). If a response is not observed within two to four weeks, imatinib should be discontinued and other therapeutic options considered.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A short trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      should also be considered in patients who were initially treated with high-dose glucocorticoids and failed to respond. Glucocorticoids should be continued during this trial in patients with potential cardiac disease, as assessed by elevated serum troponin levels",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      abnormalities on echocardiography.",
"     </li>",
"     <li>",
"      In contrast to the subgroups above,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      does NOT appear to be useful in treating the lymphocytic variant of HES or D816V c-kit mutation-positive systemic mastocytosis with eosinophilia, and should not be used in these patients [",
"      <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/45,68-70\">",
"       45,68-70",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Other chemotherapeutic and immunosuppressive agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other chemotherapeutic agents that have been used in steroid-unresponsive HES patients include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/38,48,70,71\">",
"     38,48,70,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    has also been used effectively in a small number of patients with HES, usually in combination with glucocorticoids. However, the rates of discontinuation due to drug intolerance are high [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/18\">",
"     18",
"    </a>",
"    ]. In theory, the drug blocks the proliferation of T cell clones that drive the excess eosinophilopoiesis in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In most cases, therapy with chemotherapeutics and immunosuppressive agents should be aimed at controlling organ damage rather than eradicating eosinophilia; chronic maintenance regimens are more effective and less toxic than courses of aggressive therapy aimed at inducing a hematologic remission of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     PROBLEM-SPECIFIC INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various interventions may be needed for organ-specific involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Valve replacement or repair, endomyocardectomy, or thrombectomy can provide benefit to patients with HES who develop valvular compromise or endomyocardial thrombosis or fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/38\">",
"     38",
"    </a>",
"    ]. Valve replacement with a bioprosthesis, in contrast to a mechanical valve, is indicated because thrombosis of mechanical valves has occurred despite therapeutic anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/74\">",
"     74",
"    </a>",
"    ]. Of note,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    therapy in patients with",
"    <span class=\"nowrap\">",
"     <em>",
"      FIP1L1/PDGFRA",
"     </em>",
"     -associated",
"    </span>",
"    HES may arrest progression of endomyocardial fibrosis, but does not reverse damage unless initiated before the occurrence of structural abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticoagulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antiplatelet agents is often instituted once an embolic event has occurred. Warfarin is usually initiated for a mural thrombus in the heart, or venous thrombus in an intracranial sinus. However, there is no consensus on the optimal approach. Furthermore, thrombus formation may be initiated at altered endomyocardial or endothelial sites, so thrombosis formation may not be suppressed by systemic anticoagulation when the thrombus formation is a consequence of local and not systemic proclivity to thrombosis. Anticoagulation is not usually initiated empirically in the absence of an event, as emboli can recur in adequately anticoagulated patients and efficacy is not certain [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/2\">",
"     2",
"    </a>",
"    ]. Once the eosinophilia is controlled, the need for continued anticoagulation should be determined using the same criteria used for patients without eosinophilia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7048?source=see_link\">",
"     \"Indications for antithrombotic therapy in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Hypersplenism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenectomy may be indicated in patients with hypersplenism",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pain due to splenic distension or infarcts, although it is not indicated in the routine management of HES.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     HEMATOPOIETIC CELL TRANSPLANT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited experience in the use of allogeneic hematopoietic cell transplantation, including non-myeloablative hematopoietic cell transplantation, to treat HES [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/75-80\">",
"     75-80",
"    </a>",
"    ]. This intervention may be useful in patients with treatment-refractory HES, particularly those with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    -resistant",
"    <em>",
"     PDGFRA",
"    </em>",
"    -associated disease, although the risks of the procedure do not justify its routine use at the present time. Transplantation should also be considered for patients with L-HES who develop T cell lymphoma, which may be resistant to classical chemotherapeutic regimens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30281?source=see_link\">",
"     \"Treatment and prognosis of adult T cell leukemia-lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hematopoietic cell transplantation (HCT) is associated with more morbidity than medical therapy, but for those patients who fail the available pharmacologic therapies, it offers the potential for long-term remission and possible cure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One patient with a clonal population of CD3-CD4+ T cells (L-HES) and an intraventricular thrombus was successfully treated with reduced intensity peripheral blood stem cell transplantation (HLA identical brother), and remained in remission 30 months later [",
"      <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/81\">",
"       81",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another report, two patients were treated with HCT (one with an HLA-matched unrelated donor and the other with a related donor), and remained in remission 10 months after transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The conditioning regimen used in these cases and in the above-mentioned case of lymphocytic variant HES was",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     MONITORING DURING THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monitoring of patients with HES must be individualized. In a stable patient on chronic low dose glucocorticoids, clinical assessment every 6 to 12 months may be adequate. Conversely, patients with continued symptoms and eosinophilia despite aggressive therapy may need to be evaluated weekly. In general, monthly eosinophil counts are recommended with additional testing at varied intervals depending on the therapeutic agent being used and the end organs involved. Serum troponin assays, liver enzymes, echocardiography, and pulmonary function tests should be performed every 6 to 12 months to look for occult organ involvement.",
"   </p>",
"   <p>",
"    Because of the increased risk for progression to lymphoma, patients with L-HES should be monitored every three to four months for the development of lymphocytosis and twice yearly with flow cytometry to assess an increase in the proportion of aberrant T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/82\">",
"     82",
"    </a>",
"    ]. Karyotyping (of blood or bone marrow) should be performed yearly and enlarged lymph nodes or changes in skin lesions should prompt a biopsy.",
"   </p>",
"   <p>",
"    Once in stable clinical, hematologic, and molecular remission, patients with the",
"    <span class=\"nowrap\">",
"     <em>",
"      FIP1L1/PDGFRA",
"     </em>",
"    </span>",
"    mutation on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    should be monitored approximately every three months with a complete blood count with differential and a liver profile. Troponin should be followed as well, as drug-associated cardiomyopathy has been reported as a rare complication of imatinib in patients being treated for CML [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/83\">",
"     83",
"    </a>",
"    ]. Optimally, testing for the",
"    <span class=\"nowrap\">",
"     <em>",
"      FIP1L1/PDFGRA",
"     </em>",
"    </span>",
"    transcript by PCR or FISH should be repeated every three to four months, as this is an early marker of therapeutic failure. In patients with no new symptoms, a yearly echocardiogram is suggested.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Features that portend a better prognosis include [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/10,37,38,84\">",
"     10,37,38,84",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prolonged eosinopenia in response to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      challenge.",
"     </li>",
"     <li>",
"      The absence of findings associated with myeloproliferative disorders, including elevated serum vitamin B12, abnormal leukocyte alkaline phosphatase scores, splenomegaly, cytogenetic abnormalities, myelofibrosis, and myeloid dysplasia.",
"     </li>",
"     <li>",
"      The presence of angioedema, although this observation may have been due to the inclusion of patients with the entity of episodic angioedema with eosinophilia (Gleich's syndrome) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/84\">",
"       84",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial case series of HES showed a poor prognosis, with a mean survival of nine months and a three year survival of only 12 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/73\">",
"     73",
"    </a>",
"    ]. However, most patients in early series presented with advanced disease and significant cardiovascular compromise; many deaths were due to heart failure or other complications of endomyocardial damage [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/73\">",
"     73",
"    </a>",
"    ]. Furthermore, patients with",
"    <span class=\"nowrap\">",
"     <em>",
"      FIP1L1/PDGFRA",
"     </em>",
"     -positive",
"    </span>",
"    disease, who had an extremely poor prognosis prior to the availability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    therapy, were likely overrepresented in these series.",
"   </p>",
"   <p>",
"    Earlier diagnosis of HES, close clinical and echocardiographic monitoring for heart disease, and improved medical and surgical management of cardiac complications have subsequently improved the longevity of HES patients. A 1989 French series of 40 patients (including 17 with an associated myeloproliferative syndrome) noted an 80 percent survival at five years and a 42 percent survival at 15 years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The availability of targeted therapies, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    mesylate, will likely reduce morbidity and mortality further.",
"   </p>",
"   <p>",
"    L-HES is usually a benign lymphoproliferative disorder, although several authors have reported slow progression towards full-blown T cell lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/86-88\">",
"     86-88",
"    </a>",
"    ]. Malignant progression in such patients may be heralded by the appearance of cytogenetic changes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/18/25898/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy for the hypereosinophilic syndromes (HES) is determined by the patient's presentation, laboratory findings, and the results of mutational analysis for the presence of",
"    <span class=\"nowrap\">",
"     <em>",
"      FIP1L1/PDGFRA",
"     </em>",
"     -associated",
"    </span>",
"    disease. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In the rare event that a patient presents with very high eosinophil levels or symptoms of leukostasis, emergency therapy to rapidly reduce counts should be initiated. We suggest high dose intravenous glucocorticoids as an initial intervention (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Acute reduction of very severe eosinophilia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Prior to initiating treatment, patients with aggressive disease should undergo HLA typing in preparation for possible allogeneic hematopoietic cell transplantation, and men should be offered sperm banking prior to initiation of cytotoxic therapies or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Monitoring and general care'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     FIP1L1/PDGFRA-positive HES",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For all patients with the",
"      <span class=\"nowrap\">",
"       <em>",
"        FIP1L1/PDGFRA",
"       </em>",
"      </span>",
"      mutation (even if asymptomatic), we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      mesylate for initial therapy, in preference to other available agents (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We suggest an initial oral dose of 400",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Patients with cardiac involvement should receive glucocorticoids (1 to 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily for one to two weeks) at the same time that imatinib is initiated, to prevent acute cardiac injury. Typically, symptoms improve and eosinophil counts normalize within one to two weeks. Thereafter, the dose is reduced to the lowest effective dose that maintains molecular remission, and continued indefinitely. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Imatinib mesylate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who develop secondary resistance to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      mesylate, or are intolerant of it, we suggest a trial of another tyrosine kinase inhibitor, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"       nilotinib",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If not already pursued, referral to a center with expertise in HES should be arranged. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Imatinib-resistant disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with resistant or refractory disease, allogeneic hematopoietic cell transplantation may represent the only possibility for long-term remission. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Hematopoietic cell transplant'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     FIP1L1/PDGFRA-negative HES",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For asymptomatic patients without evidence of organ involvement, subsequent management involves monitoring for the development of organ involvement every six months and vigilance for thrombotic complications. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Monitoring and general care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For symptomatic patients with",
"      <span class=\"nowrap\">",
"       <em>",
"        FIP1L1/PDGFRA",
"       </em>",
"       -negative",
"      </span>",
"      HES, including those with lymphocytic variant HES, we recommend glucocorticoids as initial therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). An exception can be made for patients with features strongly suggestive of myeloproliferative disease (see next bullet below).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      at a dose of 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day (or 60 mg once daily in adults), for one to two weeks, is a typical regimen. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If blood eosinophilia is suppressed, doses are slowly tapered to an alternate day schedule of the lowest dose that maintains control of the eosinophil count and clinical disease.",
"     </li>",
"     <li>",
"      If blood eosinophilia is not suppressed, or if the dose of glucocorticoids required to maintain a response is judged excessive (ie, either &gt;10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      poor tolerance), a second agent should be added. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Addition of steroid-sparing agents'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Second-line therapies",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with",
"      <span class=\"nowrap\">",
"       <em>",
"        FIP1L1/PDGFRA",
"       </em>",
"       -negative",
"      </span>",
"      disease who have failed glucocorticoid therapy, who require an unacceptable maintenance dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (ie, &gt;10",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      or have poor tolerance of glucocorticoids, a second-line agent should be added. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Second-line therapies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with abnormal clonal T cells (L-HES), we suggest the addition of interferon-alpha (IFNa) to glucocorticoid therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This combination targets both eosinophils and T cells. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Interferon alfa'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with myeloproliferative features in the absence of the",
"      <span class=\"nowrap\">",
"       <em>",
"        FIP1L1/PDGFRA",
"       </em>",
"      </span>",
"      rearrangement, we suggest a trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This may be initiated with a dose of 400 mg daily, and should be discontinued if there is no response within two to four weeks. As with patients with the",
"      <span class=\"nowrap\">",
"       <em>",
"        FIP1L1/PDGFRA",
"       </em>",
"      </span>",
"      mutation, glucocorticoids should be included in the regimen if there is evidence of cardiac involvement. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Imatinib'",
"      </a>",
"      above.) In the absence of a response to imatinib, alternative second-line agents include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      and IFNa.",
"     </li>",
"     <li>",
"      For other patients, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      as the second-line agent (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Hydroxyurea'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other agents used in persistent disease include anti-IL-5 (only available as part of clinical trials), anti-CD52,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , and certain chemotherapeutic agents. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Second-line therapies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For HES patients (with or without the",
"    <span class=\"nowrap\">",
"     <em>",
"      FIP1L1/PDGFRA",
"     </em>",
"    </span>",
"    fusion) who fail pharmacologic management, allogeneic hematopoietic cell transplant offers a chance of long-term remission. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Hematopoietic cell transplant'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/1\">",
"      Spry CJ, Davies J, Tai PC, et al. Clinical features of fifteen patients with the hypereosinophilic syndrome. Q J Med 1983; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/2\">",
"      Ogbogu PU, Rosing DR, Horne MK 3rd. Cardiovascular manifestations of hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007; 27:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/3\">",
"      Harley JB, Fauci AS, Gralnick HR. Noncardiovascular findings associated with heart disease in the idiopathic hypereosinophilic syndrome. Am J Cardiol 1983; 52:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/4\">",
"      Parrillo JE, Borer JS, Henry WL, et al. The cardiovascular manifestations of the hypereosinophilic syndrome. Prospective study of 26 patients, with review of the literature. Am J Med 1979; 67:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/5\">",
"      Klion AD, Bochner BS, Gleich GJ, et al. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol 2006; 117:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/6\">",
"      Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/7\">",
"      Griffin JH, Leung J, Bruner RJ, et al. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci U S A 2003; 100:7830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/8\">",
"      Cortes J, Ault P, Koller C, et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood 2003; 101:4714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/9\">",
"      Pardanani A, Reeder T, Porrata LF, et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 2003; 101:3391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/10\">",
"      Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003; 101:4660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/11\">",
"      Klion AD, Robyn J, Akin C, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 2004; 103:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/12\">",
"      Jovanovic JV, Score J, Waghorn K, et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 2007; 109:4635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/13\">",
"      Cervetti G, Galimberti S, Carulli G, Petrini M. Imatinib therapy in Hypereosinophilic Syndrome: a case of molecular remission. Leuk Res 2005; 29:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/14\">",
"      von Bubnoff N, Sandherr M, Schlimok G, et al. Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia. Leukemia 2005; 19:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/15\">",
"      Baccarani M, Cilloni D, Rondoni M, et al. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 2007; 92:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/16\">",
"      Pitini V, Arrigo C, Azzarello D, et al. Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes. Blood 2003; 102:3456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/17\">",
"      Vandenberghe P, Wlodarska I, Michaux L, et al. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia 2004; 18:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/18\">",
"      Ogbogu PU, Bochner BS, Butterfield JH, et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 2009; 124:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/19\">",
"      Simon D, Salemi S, Yousefi S, Simon HU. Primary resistance to imatinib in Fip1-like 1-platelet-derived growth factor receptor alpha-positive eosinophilic leukemia. J Allergy Clin Immunol 2008; 121:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/20\">",
"      Straumann A, Bussmann C, Conus S, et al. Anti-TNF-alpha (infliximab) therapy for severe adult eosinophilic esophagitis. J Allergy Clin Immunol 2008; 122:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/21\">",
"      Metzgeroth G, Walz C, Erben P, et al. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br J Haematol 2008; 143:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/22\">",
"      Helbig G, Moskwa A, Swiderska A, et al. Weekly imatinib dosage for chronic eosinophilic leukaemia expressing FIP1L1-PDGFRA fusion transcript: extended follow-up. Br J Haematol 2009; 145:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/23\">",
"      Intermesoli T, Delaini F, Acerboni S, et al. A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes. Br J Haematol 2009; 147:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/24\">",
"      Klion AD, Robyn J, Maric I, et al. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing. Blood 2007; 110:3552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/25\">",
"      Hensley ML, Ford JM. Imatinib treatment: specific issues related to safety, fertility, and pregnancy. Semin Hematol 2003; 40:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/26\">",
"      Pye SM, Cortes J, Ault P, et al. The effects of imatinib on pregnancy outcome. Blood 2008; 111:5505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/27\">",
"      Apperley J. Issues of imatinib and pregnancy outcome. J Natl Compr Canc Netw 2009; 7:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/28\">",
"      Christopoulos C, Dimakopoulou V, Rotas E. Primary ovarian insufficiency associated with imatinib therapy. N Engl J Med 2008; 358:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/29\">",
"      Ramasamy K, Hayden J, Lim Z, et al. Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy. Br J Haematol 2007; 137:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/30\">",
"      Seshadri T, Seymour JF, McArthur GA. Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome. N Engl J Med 2004; 351:2134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/31\">",
"      Kobayashi K, Takebayashi C, Miyata S, et al. Successful delivery after planned discontinuation of imatinib in a patient with chronic myeloid leukemia. Intern Med 2009; 48:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/32\">",
"      Baumgartner C, Gleixner KV, Peter B, et al. Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha. Exp Hematol 2008; 36:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/33\">",
"      Stover EH, Chen J, Lee BH, et al. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood 2005; 106:3206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/34\">",
"      Lierman E, Folens C, Stover EH, et al. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood 2006; 108:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/35\">",
"      Ikezoe T, Togitani K, Tasaka T, et al. Successful treatment of imatinib-resistant hypereosinophilic syndrome with nilotinib. Leuk Res 2010; 34:e200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/36\">",
"      Lierman E, Michaux L, Beullens E, et al. FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. Leukemia 2009; 23:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/37\">",
"      Parrillo JE, Lawley TJ, Frank MM, et al. Immunologic reactivity in the hypereosinophilic syndrome. J Allergy Clin Immunol 1979; 64:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/38\">",
"      Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood 1994; 83:2759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/39\">",
"      Prin L, Lefebvre P, Gruart V, et al. Heterogeneity of human eosinophil glucocorticoid receptor expression in hypereosinophilic patients: absence of detectable receptor correlates with resistance to corticotherapy. Clin Exp Immunol 1989; 78:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/40\">",
"      Jain N, Cortes J, Quint&aacute;s-Cardama A, et al. Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status. Leuk Res 2009; 33:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/41\">",
"      Schooley RT, Flaum MA, Gralnick HR, Fauci AS. A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. II. Clinical manifestations. Blood 1981; 58:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/42\">",
"      Dahabreh IJ, Giannouli S, Zoi C, et al. Management of hypereosinophilic syndrome: a prospective study in the era of molecular genetics. Medicine (Baltimore) 2007; 86:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/43\">",
"      Butterfield JH. Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis. Acta Haematol 2005; 114:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/44\">",
"      Schanden&eacute; L, Roufosse F, de Lavareille A, et al. Interferon alpha prevents spontaneous apoptosis of clonal Th2 cells associated with chronic hypereosinophilia. Blood 2000; 96:4285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/45\">",
"      Roufosse F, Cogan E, Goldman M. Recent advances in pathogenesis and management of hypereosinophilic syndromes. Allergy 2004; 59:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/46\">",
"      Broxmeyer HE, Lu L, Platzer E, et al. Comparative analysis of the influences of human gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-E) and granulocyte-macrophage (CFU-GM) progenitor cells. J Immunol 1983; 131:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/47\">",
"      Parronchi P, Mohapatra S, Sampognaro S, et al. Effects of interferon-alpha on cytokine profile, T cell receptor repertoire and peptide reactivity of human allergen-specific T cells. Eur J Immunol 1996; 26:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/48\">",
"      Butterfield JH, Weiler CR. Treatment of hypereosinophilic syndromes--the first 100 years. Semin Hematol 2012; 49:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/49\">",
"      Malbrain ML, Van den Bergh H, Zach&eacute;e P. Further evidence for the clonal nature of the idiopathic hypereosinophilic syndrome: complete haematological and cytogenetic remission induced by interferon-alpha in a case with a unique chromosomal abnormality. Br J Haematol 1996; 92:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/50\">",
"      Butterfield JH, Gleich GJ. Interferon-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome. Ann Intern Med 1994; 121:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/51\">",
"      Bockenstedt PL, Santinga JT, Bolling SF. alpha-Interferon treatment for idiopathic hypereosinophilic syndrome. Am J Hematol 1994; 45:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/52\">",
"      Canonica GW, Passalacqua G, Pronzato C, et al. Effective long-term alpha-interferon treatment for hypereosinophilic syndrome. J Allergy Clin Immunol 1995; 96:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/53\">",
"      Butterfield JH, Weiler CR. Use of pegylated interferon in hypereosinophilic syndrome. Leuk Res 2012; 36:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/54\">",
"      Klion AD, Law MA, Noel P, et al. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 2004; 103:2939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/55\">",
"      Rothenberg ME, Klion AD, Roufosse FE, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008; 358:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/56\">",
"      Kay AB, Klion AD. Anti-interleukin-5 therapy for asthma and hypereosinophilic syndrome. Immunol Allergy Clin North Am 2004; 24:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/57\">",
"      Pl&ouml;tz SG, Simon HU, Darsow U, et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 2003; 349:2334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/58\">",
"      Garrett JK, Jameson SC, Thomson B, et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol 2004; 113:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/59\">",
"      Stein ML, Villanueva JM, Buckmeier BK, et al. Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. J Allergy Clin Immunol 2008; 121:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/60\">",
"      Mehr S, Rego S, Kakakios A, et al. Treatment of a case of pediatric hypereosinophilic syndrome with anti-interleukin-5. J Pediatr 2009; 155:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/61\">",
"      Roufosse FE, Kahn JE, Gleich GJ, et al. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol 2013; 131:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/62\">",
"      Roufosse F, de Lavareille A, Schanden&eacute; L, et al. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome. J Allergy Clin Immunol 2010; 126:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/63\">",
"      Verstovsek S, Tefferi A, Kantarjian H, et al. Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res 2009; 15:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/64\">",
"      Kalac M, Quint&aacute;s-Cardama A, Vrhovac R, et al. A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia. Cancer 2007; 110:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/65\">",
"      Pitini V, Teti D, Arrigo C, Righi M. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report. Br J Haematol 2004; 127:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/66\">",
"      Score J, Curtis C, Waghorn K, et al. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia 2006; 20:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/67\">",
"      Curtis CE, Grand FH, Musto P, et al. Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia. Br J Haematol 2007; 138:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/68\">",
"      Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003; 102:3093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/69\">",
"      Akin C, Brockow K, D'Ambrosio C, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 2003; 31:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/70\">",
"      Vaklavas C, Tefferi A, Butterfield J, et al. 'Idiopathic' eosinophilia with an Occult T-cell clone: prevalence and clinical course. Leuk Res 2007; 31:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/71\">",
"      Razaq W, Beautyman E. Successful treatment of refractory idiopathic hypereosinophilic syndrome with etoposide. Am J Ther 2009; 16:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/72\">",
"      Nadarajah S, Krafchik B, Roifman C, Horgan-Bell C. Treatment of hypereosinophilic syndrome in a child using cyclosporine: implication for a primary T-cell abnormality. Pediatrics 1997; 99:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/73\">",
"      Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/74\">",
"      Boustany CW Jr, Murphy GW, Hicks GL Jr. Mitral valve replacement in idiopathic hypereosinophilic syndrome. Ann Thorac Surg 1991; 51:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/75\">",
"      Esteva-Lorenzo FJ, Meehan KR, Spitzer TR, Mazumder A. Allogeneic bone marrow transplantation in a patient with hypereosinophilic syndrome. Am J Hematol 1996; 51:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/76\">",
"      Fukushima T, Kuriyama K, Ito H, et al. Successful bone marrow transplantation for idiopathic hypereosinophilic syndrome. Br J Haematol 1995; 90:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/77\">",
"      Sigmund DA, Flessa HC. Hypereosinophilic syndrome: successful allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/78\">",
"      Archimbaud E, Guyotat D, Guillaume C, et al. Hypereosinophilic syndrome with multiple organ dysfunction treated by allogeneic bone marrow transplantation. Am J Hematol 1988; 27:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/79\">",
"      Ueno NT, Anagnostopoulos A, Rond&oacute;n G, et al. Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome. Br J Haematol 2002; 119:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/80\">",
"      Halaburda K, Prejzner W, Szatkowski D, et al. Allogeneic bone marrow transplantation for hypereosinophilic syndrome: long-term follow-up with eradication of FIP1L1-PDGFRA fusion transcript. Bone Marrow Transplant 2006; 38:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/81\">",
"      Bergua JM, Prieto-Pliego E, Rom&aacute;n-Barber&aacute; A, et al. Resolution of left and right ventricular thrombosis secondary to hypereosinophilic syndrome (lymphoproliferative variant) with reduced intensity conditioning allogenic stem cell transplantation. Ann Hematol 2008; 87:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/82\">",
"      Roufosse F, Cogan E, Goldman M. Lymphocytic variant hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007; 27:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/83\">",
"      Atallah E, Durand JB, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007; 110:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/84\">",
"      Parrillo JE, Fauci AS, Wolff SM. Therapy of the hypereosinophilic syndrome. Ann Intern Med 1978; 89:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/85\">",
"      Lefebvre C, Bletry O, Degoulet P, et al. [Prognostic factors of hypereosinophilic syndrome. Study of 40 cases]. Ann Med Interne (Paris) 1989; 140:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/86\">",
"      Roufosse F, Cogan E, Goldman M. The hypereosinophilic syndrome revisited. Annu Rev Med 2003; 54:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/87\">",
"      Simon HU, Pl&ouml;tz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 1999; 341:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/18/25898/abstract/88\">",
"      Roufosse F, Schanden&eacute; L, Sibille C, et al. Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome. Br J Haematol 2000; 109:540.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2210 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.81.197.98-2D46B63E26-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_18_25898=[""].join("\n");
var outline_f25_18_25898=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MONITORING AND GENERAL CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Monitoring for organ involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Vigilance for thrombotic complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Planning for disease progression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ACUTE REDUCTION OF VERY SEVERE EOSINOPHILIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      OVERVIEW OF PHARMACOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT OF PDGFRA-POSITIVE HES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Imatinib mesylate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Caution in patients with cardiac disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3133669\">",
"      - Family planning",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Imatinib-resistant disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Other tyrosine kinase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT OF OTHER FORMS OF HES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Addition of steroid-sparing agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Second-line therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Hydroxyurea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Interferon alfa",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Anti-IL-5",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Anti-CD52",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Imatinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Other chemotherapeutic and immunosuppressive agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      PROBLEM-SPECIFIC INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      HEMATOPOIETIC CELL TRANSPLANT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      MONITORING DURING THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Survival",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      FIP1L1/PDGFRA-positive HES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      FIP1L1/PDGFRA-negative HES",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Second-line therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24745?source=related_link\">",
"      Approach to the patient with eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27290?source=related_link\">",
"      Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19576?source=related_link\">",
"      Hyperleukocytosis and leukostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7048?source=related_link\">",
"      Indications for antithrombotic therapy in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7034?source=related_link\">",
"      Initial treatment of chronic myeloid leukemia in chronic phase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27111?source=related_link\">",
"      Interferon alpha for the treatment of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41225?source=related_link\">",
"      Overview of the treatment of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30281?source=related_link\">",
"      Treatment and prognosis of adult T cell leukemia-lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30442?source=related_link\">",
"      Treatment of relapsed or refractory chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_18_25899="Homesickness resources for families";
var content_f25_18_25899=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77248&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77248&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Homesickness resources for families",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        American Camp Association Web site. Available at: www.acacamps.org.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CampParents.org: an American Camp Association online resource for families. Available at: www.campparents.org.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Find A Camp: the American Camp Association's camp locator with data from more than 2400 accredited camps. Available at: www.campparents.org. Also available is a camp search engine that includes both accredited and nonaccredited camps that are located in both the US and Canada. Available at: www.MySummerCamps.com.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pravda M, Weiland J. Off to Camp, JSP Publishing, Cincinnati, OH 1990.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thorn C. Second Home: Life in a Boarding School, Avocus Publishing, Gilsum, NH 2003.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thurber CA. The Secret Ingredients of Summer Camp Success: How to Have the Most Fun With the Least Homesickness [DVD/CD], American Camp Association, Martinsville, IN 2006.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thurber CA, Malinowski JC. The Summer Camp Handbook: Everything You Need to Know to Find, Choose, and Get Ready for Overnight Camp -- and Skip the Homesickness, Perspective Publishing, Los Angeles, CA 2000.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Thurber CA, Walton E, the Council on School Health. Preventing and treating homesickness. Pediatrics 2007; 119:192. Copyright &copy; 2007 by the AAP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_18_25899=[""].join("\n");
var outline_f25_18_25899=null;
var title_f25_18_25900="Exchange lists";
var content_f25_18_25900=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52063&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52063&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Calories and macronutrient content of exchange lists",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Group",
"       </td>",
"       <td class=\"subtitle1\">",
"        Carbohydrate, grams",
"       </td>",
"       <td class=\"subtitle1\">",
"        Protein, grams",
"       </td>",
"       <td class=\"subtitle1\">",
"        Fat, grams",
"       </td>",
"       <td class=\"subtitle1\">",
"        Calories, grams",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Carbohydrate group",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Starch",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        0 to 1",
"       </td>",
"       <td>",
"        80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fruit",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Milk",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        varies",
"       </td>",
"       <td>",
"        90 to 150",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Other carbohydrates",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        varies",
"       </td>",
"       <td>",
"        varies",
"       </td>",
"       <td>",
"        varies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Non-starchy vegetables",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Meat and meat substitutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Very lean",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        0 to 1",
"       </td>",
"       <td>",
"        35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lean",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        55",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Medium-fat",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        75",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        High-fat",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Fat group",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        45",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_18_25900=[""].join("\n");
var outline_f25_18_25900=null;
var title_f25_18_25901="Clues RD 2nd grade and up";
var content_f25_18_25901=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54976&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54976&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clues to dyslexia from second grade on",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Problems in speaking",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mispronunciation of long, unfamiliar, or complicated words; the",
"       <em>",
"        fracturing",
"       </em>",
"       of words--leaving out parts of words or confusing the order of the parts of words; for example",
"       <em>",
"        aluminum",
"       </em>",
"       becomes",
"       <em>",
"        amulium",
"       </em>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Speech that is not fluent--pausing or hesitating often when speaking, lots of",
"       <em>",
"        um's",
"       </em>",
"       during speech, no glibness",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       The use of imprecise language, such as vague references to",
"       <em>",
"        stuff",
"       </em>",
"       or",
"       <em>",
"        things",
"       </em>",
"       instead of the proper name of an object",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Not being able to find the exact word, such as confusing words that sound alike: saying",
"       <em>",
"        tornado",
"       </em>",
"       instead of",
"       <em>",
"        volcano,",
"       </em>",
"       substituting",
"       <em>",
"        lotion",
"       </em>",
"       for",
"       <em>",
"        ocean,",
"       </em>",
"       or",
"       <em>",
"        humanity",
"       </em>",
"       for",
"       <em>",
"        humidity",
"       </em>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       The need for time to summon an oral response or the inability to come up with a verbal response quickly when questioned",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Difficulty in remembering isolated pieces of verbal information (rote memory)--trouble remembering dates, names, telephone numbers, random lists",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Problems in reading",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Very slow progress in acquiring reading skills",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       The lack of a strategy to read new words",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Trouble reading",
"       <em>",
"        unknown",
"       </em>",
"       (new, unfamiliar) words that must be sounded out; making wild stabs or guesses at reading a word; failure to systematically sound out words",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       The inability to read small \"function\" words, such as",
"       <em>",
"        that,",
"       </em>",
"       <em>",
"        an,",
"       </em>",
"       <em>",
"        in",
"       </em>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stumbling on reading multisyllable words, or the failure to come close to sounding out the full word",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Omitting parts of words when reading; the failure to decode parts within a word, as if someone had chewed a hole in the middle of the word, such as",
"       <em>",
"        conible",
"       </em>",
"       for",
"       <em>",
"        convertible",
"       </em>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A terrific fear of reading out loud; the avoidance of oral reading",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Oral reading filled with substitutions, omissions, and mispronunciations",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Oral reading that is choppy and labored, not smooth or fluent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Oral reading that lacks inflection and sounds like the reading of a foreign language",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A reliance on context to discern the meaning of what is read",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A better ability to understand words",
"       <em>",
"        in context",
"       </em>",
"       than to read",
"       <em>",
"        isolated",
"       </em>",
"       single words",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Disproportionately poor performance on multiple-choice tests",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       The inability to finish tests on time",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       The substitution of words with the same meaning for words in the text he can't pronounce, such as",
"       <em>",
"        car",
"       </em>",
"       for",
"       <em>",
"        automobile",
"       </em>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Disastrous spelling, with words not resembling true spelling; some spellings may be missed by spell check",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Trouble reading mathematics word problems",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Reading that is very slow and tiring",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Homework that never seems to end, or with parents often recruited as readers",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Messy handwriting despite what may be an excellent facility at word processing--nimble fingers",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Extreme difficulty learning a foreign language",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A lack of enjoyment of reading, and the avoidance of reading books or even a sentence",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       The avoidance of reading for pleasure, which seems too exhausting",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Reading whose accuracy improves over time, though it continues to lack fluency and is laborious",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lowered self-esteem, with pain that is not always visible to others",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A history of reading, spelling, and foreign language problems in family members",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Shaywitz S. Overcoming Dyslexia: A New and Complete Science-Based Program for Reading Problems at Any Level. Copyright &copy; 2003 by Sally Shaywitz, M.D. Used with permission of Alfred A. Knopf, a division of Random House, Inc. For on-line information about other Random House, Inc. books and authors, see the Internet Web site at www.randomhouse.com.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_18_25901=[""].join("\n");
var outline_f25_18_25901=null;
var title_f25_18_25902="Lentigo maligna melanoma PI";
var content_f25_18_25902=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F79649&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F79649&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lentigo maligna melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 218px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lentigo maligna melanoma usually arises in areas of sun-damaged skin, particularly on the head and neck.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James C Shaw, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_18_25902=[""].join("\n");
var outline_f25_18_25902=null;
var title_f25_18_25903="Dysuria prepubertal male";
var content_f25_18_25903=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 565px\">",
"   <div class=\"ttl\">",
"    Dysuria in the prepubertal male without conjunctivitis, arthritis, or generalized rash",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 545px; height: 593px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_18_25903=[""].join("\n");
var outline_f25_18_25903=null;
